Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.73 Million EUR | 502.93% |
| 2022 | 785 Thousand EUR | 163.42% |
| 2021 | 298 Thousand EUR | -90.36% |
| 2020 | 3.09 Million EUR | 3297.8% |
| 2019 | 91 Thousand EUR | 15.19% |
| 2018 | 79 Thousand EUR | 2533.33% |
| 2017 | 3000.00 EUR | -99.54% |
| 2016 | 646 Thousand EUR | 6360.0% |
| 2015 | 10 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 35 Thousand EUR | 0.0% |
| 2023 Q4 | 490 Thousand EUR | 0.0% |
| 2023 FY | 4.73 Million EUR | 502.93% |
| 2023 Q2 | 4.24 Million EUR | 0.0% |
| 2022 Q4 | 150 Thousand EUR | 0.0% |
| 2022 FY | 785 Thousand EUR | 163.42% |
| 2022 Q2 | 635 Thousand EUR | 0.0% |
| 2021 FY | 298 Thousand EUR | -90.36% |
| 2021 Q2 | 148 Thousand EUR | 0.0% |
| 2021 Q4 | 150 Thousand EUR | 0.0% |
| 2020 Q4 | 2.97 Million EUR | 0.0% |
| 2020 FY | 3.09 Million EUR | 3297.8% |
| 2020 Q2 | 121 Thousand EUR | 0.0% |
| 2019 FY | 91 Thousand EUR | 15.19% |
| 2019 Q4 | 45 Thousand EUR | 0.0% |
| 2019 Q2 | 46 Thousand EUR | 0.0% |
| 2018 FY | 79 Thousand EUR | 2533.33% |
| 2018 Q4 | 79 Thousand EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2017 Q4 | -37 Thousand EUR | 0.0% |
| 2017 FY | 3000.00 EUR | -99.54% |
| 2017 Q2 | 40 Thousand EUR | 0.0% |
| 2016 Q1 | 161.5 Thousand EUR | 0.0% |
| 2016 FY | 646 Thousand EUR | 6360.0% |
| 2016 Q4 | 123 Thousand EUR | 0.0% |
| 2016 Q2 | 161.5 Thousand EUR | 0.0% |
| 2015 Q4 | 161.5 Thousand EUR | 0.0% |
| 2015 FY | 10 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -2.004% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -2.424% |
| Adocia SA | 2.15 Million EUR | -120.14% |
| Aelis Farma SA | 9.05 Million EUR | 47.725% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -50.206% |
| genOway Société anonyme | 20.04 Million EUR | 76.39% |
| IntegraGen SA | 12.53 Million EUR | 62.249% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -1477.488% |
| Neovacs S.A. | 533.41 Thousand EUR | -787.307% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -181.472% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -23808.87% |
| Sensorion SA | 4.74 Million EUR | 0.212% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -1497.2% |
| TME Pharma N.V. | 17 Thousand EUR | -27741.176% |
| TheraVet SA | 1.07 Million EUR | -339.031% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -162.944% |
| argenx SE | 1.13 Billion EUR | 99.583% |
| BioSenic S.A. | 543 Thousand EUR | -771.639% |
| Celyad Oncology SA | 102 Thousand EUR | -4540.196% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 98.026% |
| Genfit S.A. | 28.56 Million EUR | 83.431% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -126.785% |
| Innate Pharma S.A. | 51.9 Million EUR | 90.881% |
| Inventiva S.A. | 17.47 Million EUR | 72.919% |
| MaaT Pharma SA | 2.22 Million EUR | -112.433% |
| MedinCell S.A. | 9.16 Million EUR | 48.33% |
| Nanobiotix S.A. | 30.05 Million EUR | 84.254% |
| Onward Medical N.V. | 532 Thousand EUR | -789.662% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 66.649% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -112.528% |
| Oxurion NV | 263 Thousand EUR | -1699.62% |
| Pharming Group N.V. | 245.31 Million EUR | 98.071% |
| Poxel S.A. | 1.98 Million EUR | -138.92% |
| GenSight Biologics S.A. | 1.26 Million EUR | -273.56% |
| Transgene SA | 1.18 Million EUR | -299.747% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.91% |
| Valneva SE | 153.71 Million EUR | 96.921% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 230.746% |